A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial

• Published in: BMC anesthesiology 2023-09, Vol.23 (1), p.1-304, Article 304
• Main Authors: Lin, Zhonglan, Li, Shuxin, Zhou, Yun, Lu, Xinlei, Yang, Bin, Yu, Zhengwei, Cheng, Yuan, Sun, Jianliang
• Format: Article
• Language: English
• Subjects: Ablation; Analgesia; Anesthesia; Blood pressure; Cancer therapies; Chronic obstructive pulmonary disease; Clinical trials; Comparative analysis; Dexmedetomidine; Double-blind studies; Drug dosages; Esketamine; Heart beat; Heart rate; Homeopathy; Hospitals; Hypertension; Informed consent; Lung cancer; Lung tumor radiofrequency ablation; Lungs; Materia medica and therapeutics; Nausea; Pain; Pain perception; Patient satisfaction; Patients; Performance evaluation; Pneumothorax; Radiofrequency ablation; Sedation; Sufentanil; Surgery; Therapeutics; Tumors; Vomiting
• ISSN: 1471-2253; 1471-2253
• DOI: 10.1186/s12871-023-02266-y

Objective To observe and evaluate the effectiveness and safety of Esketamine or Sufentanil combined with Dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA) to provide a clinical basis for the optimization of sedation and analgesia in lung tumor PRFA protocols outside the operating room. Methods In this trial, 44 patients aged 37 to 84 undergoing lung tumor PRFA were enrolled and assigned to Group E (n = 22, Esketamine 0.2 mg/kg) or Group S (n = 22,Sufentanil 0.1 [mu]g/kg ). Dexmedetomidine was infused intravenously as a sedative in both groups. The modified observer's assessment of alertness and sedation scale (MOAAS), physical movement pain scale, intraoperative vital signs, anesthesia recovery time, radiologist and patient satisfaction rates, incidence of respiratory depression, and incidence of postoperative nausea and vomiting were recorded. Results Although there was no significant difference in the physical movement pain scale, blood oxygen saturation or incidence of perioperative adverse events between the two groups during ablation, the MOAAS, mean arterial pressure (MAP) and heart rate (HR) were higher in Group E than in Group S. The anesthesia recovery time was shorter in Group E than in Group S, and radiologist satisfaction was better in Group E than in Group S, but there was no significant difference between the two groups in terms of patient satisfaction. Conclusion Esketamine or Sufentanil combined with Dexmedetomidine is safe for lung tumor PRFA. However, in elderly patients with multiple underlying diseases, low-dose Esketamine combined with Dexmedetomidine has fewer hemodynamic effects on patients, milder respiratory depression, shorter recovery time, and better radiologist satisfaction because of its better controllability of sedation depth. Trial registration Chinese Clinical Trial Registry (Registration number#ChiCTR ChiCTR21000500 21); Date of Registration: 16/08/2021 Keywords: Esketamine, Dexmedetomidine, Sedation, Analgesia, Lung tumor radiofrequency ablation